Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 4/20 | 0.44 |
| ▸ | RXRB | P28702 | 4/20 | 0.44 |
| ▸ | RXRG | P48443 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | RARA | P10276 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | RARG | P13631 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776048 | 0.95 | GABRA1 (0.50) | CA5AGABRA1GABRB2RXRARXRB | |
| SCHEMBL13043940 | 0.91 | RXRA (0.52) | CA5ARXRARXRBRXRGMAPT | |
| SCHEMBL1204749 | 0.87 | CA5A (0.64) | CA5AGABRA1GABRB2RXRARXRB | |
| SCHEMBL1204943 | 0.87 | RXRB (0.43) | CA5AGABRA1GABRB2RXRARXRB | |
| SCHEMBL16261236 | 0.87 | RXRA (0.50) | CA5AGABRA1GABRB2RXRARXRB | |
| SCHEMBL1204263 | 0.86 | NOTUM (0.47) | MAPTMEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL12187542 | 0.85 | CES2 (0.57) | CA5AGABRA1GABRB2RXRARXRB | |
| SCHEMBL12187779 | 0.85 | CA5A (0.40) | CA5AGABRA1GABRB2RXRARXRB | |
| SCHEMBL21484024 | 0.85 | GAA (0.42) | CA5AGABRA1GABRB2RXRARXRB | |
| SCHEMBL31072829 | 0.85 | ACHE (0.44) | CA5AGABRA1GABRB2RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230288847-A1 | ELECTROPHOTOGRAPHIC PHOTORECEPTOR, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS | FUJIFILM BUSINESS INNOVATION CORP. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230288824-A1 | ELECTROPHOTOGRAPHIC PHOTORECEPTOR, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS | FUJIFILM BUSINESS INNOVATION CORP. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230280668-A1 | ELECTROPHOTOGRAPHIC PHOTORECEPTOR, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS | FUJIFILM BUSINESS INNOVATION CORP. (JP) | 2023-09-07 | — | — | US | disclosed |
| US-20230266684-A1 | IMAGE FORMING UNIT AND IMAGE FORMING APPARATUS | FUJIFILM BUSINESS INNOVATION CORP. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20230266683-A1 | ELECTROPHOTOGRAPHIC PHOTORECEPTOR, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS | FUJIFILM BUSINESS INNOVATION CORP. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20230266684-A1 | IMAGE FORMING UNIT AND IMAGE FORMING APPARATUS | FUJIFILM BUSINESS INNOVATION CORP. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20230195003-A1 | ELECTROPHOTOGRAPHIC PHOTORECEPTOR, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS | FUJIFILM BUSINESS INNOVATION CORP. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230195003-A1 | ELECTROPHOTOGRAPHIC PHOTORECEPTOR, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS | FUJIFILM BUSINESS INNOVATION CORP. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20180120701-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE FILM, MASK BLANK INCLUDING ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE FILM, PATTERN FORMING METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
| US-9079906-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2015-07-14 | — | — | US | disclosed |
| US-8076336-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI-AVENTIS (FR) | 2011-12-13 | — | — | US | disclosed |
| US-8076336-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI-AVENTIS (FR) | 2011-12-13 | — | — | US | disclosed |
| US-8076336-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI-AVENTIS (FR) | 2011-12-13 | — | — | US | disclosed |
| CN-101981034-A | Triazolopyridazines as PAR1 inhibitors, their preparation and their use as medicaments | SANOFI AVENTIS | 2011-02-23 | — | — | CN | disclosed |
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| WO-2009097970-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2000026172-A1 | TRIENOIC RETINOID COMPOUNDS AS RETINOIC ACID RECEPTOR ANTAGONISTS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-05-11 | — | — | WO | disclosed |
| US-5998654-A | SKIN DISORDERS; ANTICANCER AGENTS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | CA5A 2267/4885GABRA1 1485/4885GABRB2 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.